← SynDRA
VERCIRNON
SynDRA canonical compound SYN0034167 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | CCR9 |
| Mechanism of action | CC chemokine receptor antagonist |
All known targets
Mechanisms of action (all sources)
- CCR9 ANTAGONIST
- C-C chemokine receptor type 9 antagonist
- CC chemokine receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CCR2
- ADGRF1
- GPR119
- S1PR1
- OGG1
- NEIL2
- NEIL1
- MUTYH
- MPG
- HDAC6
- GPR35
- GLP1R
- ADRA2A
- FPR2
- FFAR4
- CX3CR1
- CCR7
- C5AR1
- APLNR
- AGTR1
- ADRB2
- TDG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Verecimon
- CCX-282-B
- CCX282
- GSK-1605786
- GSK1605786
- MWI54OUA12
- vercirnonum
- RefChem:193977
- DTXCID50142626
- Traficet-EN
- CCX282-B
- VERCIRNON [INN]
- VERCIRNON [USAN]
- VERCIRNON [WHO-DD]
- SCHEMBL342225
- GTPL9046
- orb1307619
- GSK'786
- JRWROCIMSDXGOZ-UHFFFAOYSA-N
- GLXC-10244
- YCB39473
- BDBM50398334
- NSC840236
- CS-4963
- NSC-840236
- NCGC00485483-01
- DA-22939
- HY-15724
- MS-28019
- F81794
- T17225
- BRD-K47929404-001-01-0
- GSK1605786A
- 9NQF0M8R0M
- RefChem:933977
- GSK-1605786A
- Vercirnon Sodium
- vercirnon sodium
Look up VERCIRNON in the interactive SynDRA portal →